In colorectal and NSCLC cell lines, upon treatment with Navitoclax the BAX:BCL-XL complexes were disrupted hence relieving the suppression of active BAX by BCL-XL (Fig. 3e, f). The gene discussed is BCL2L1; the disease is non-small cell lung carcinoma.